Skin Toxicity Clinical Trial
Official title:
Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27
Our study aims to clarify the impact of the use of a standard sunbed according to new EU
guideline EN 60335-2-27 and possibly discount the positive effects of tanning beds. We plan
to investigate the serum elevation of 25(OH)D under sunbed use, respecting the new
recommendations for the exposure plan for different skin types according to EN 60335-2-27.
The use of a sunbed will be compared to a control group not using a sunbed in the
observation period.
- Trial with medical device
We will compare to baseline changes in serum vitamin D and health-related quality of life using a control group and an intervention group. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04929834 -
Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities
|
N/A | |
Completed |
NCT04929847 -
Novel Skin Care for Chemotherapy- Related Dermatologic Toxicities
|
N/A | |
Not yet recruiting |
NCT03606954 -
Potency of Topical Corticosteroids in Combination Preparations
|
Phase 4 | |
Completed |
NCT03448731 -
Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)
|
Phase 2 | |
Recruiting |
NCT05109858 -
Skin Toxicity by Oncological Therapies
|
||
Completed |
NCT00871429 -
Skin Care for Cancer Patients: A Product Satisfaction Survey
|
N/A | |
Recruiting |
NCT04469075 -
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
|
Phase 2 | |
Recruiting |
NCT04650256 -
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
|
N/A | |
Terminated |
NCT01317433 -
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
|
N/A | |
Active, not recruiting |
NCT03167268 -
Panitumumab Skin Toxicity Prevention Trial
|
Phase 2 | |
Recruiting |
NCT06118047 -
Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
|
Phase 2 |